This is an old revision of this page, as edited by Michael7604 (talk | contribs) at 21:51, 7 January 2024 (recategorized from Chlorobenzenes to Chloroarenes). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 21:51, 7 January 2024 by Michael7604 (talk | contribs) (recategorized from Chlorobenzenes to Chloroarenes)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)Names | |
---|---|
Preferred IUPAC name {5--4-(propan-2-yl)-1--1H-imidazol-2-yl}methyl carbamate | |
Identifiers | |
CAS Number | |
3D model (JSmol) | |
ChEMBL | |
ChemSpider | |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
InChI
| |
SMILES
| |
Properties | |
Chemical formula | C20H20Cl2N4O2S |
Molar mass | 451.37 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). N verify (what is ?) Infobox references |
Capravirine was a non-nucleoside reverse transcriptase inhibitor which reached phase II trials before development was discontinued by Pfizer. Both phase IIb trials which were conducted failed to demonstrate that therapy with capravirine provided any significant advantage over existing triple-drug HIV therapies, and pharmacology studies showed that capravirine may interact with other HIV drugs.
References
- PubChem. "Capravirine". pubchem.ncbi.nlm.nih.gov. Retrieved 2019-06-02.
- "Capravirine - Anti-Retroviral Drug". Drug Development Technology. Retrieved 2019-06-02.
- "Capravirine - Anti-Retroviral Drug". Drug Development Technology. Retrieved 2019-06-02.
- "A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. 23 June 2005. Retrieved 2019-06-02.
This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it. |